ALDX Aldeyra Therapeutics, Inc. Insider Trading

CEO Todd C Brady bought 250,000 shares of ALDX at $1.67 on 2026-06-03, expanding stake to 1.72M shares; stock down -72.3% from 52-week high.

Todd C Brady, President and CEO, purchased 250,000 shares at $1.67 for a total value of $418,450.00, increasing his holdings from 1.47M to 1.72M shares. The stock currently trades at $1.71, down -72.3% from its 52-week high of $6.18, and has declined -58.6% over the past 90 days. The company reported a net loss of $-3.5M over its most recent full fiscal year and remains unprofitable. Brady's prior trade history at ALDX consists of two sells (2024-03-12 and 2024-03-11), neither of which were well-timed at the 90-day horizon, as the stock rose after both sales. This open-market purchase by the CEO occurs against a backdrop of significant stock-price erosion and persistent losses, warranting monitoring of whether additional insider activity or operational developments follow.

Director Douglas Richard buys 70.0K shares of ALDX at $1.40; holds 195.0K post-trade. Stock down 73.1% from 52-week high.

Director Douglas Richard purchased 70,000 shares at $1.40 on 2026-03-19, increasing his position from 125,000 to 195,000 shares (+56.0% increase in holdings). The transaction occurred while Aldeyra Therapeutics reported a net loss of $7.7M over its most recent full fiscal year, indicating the company remains unprofitable. The stock has declined 73.1% from its 52-week high of $6.72 and is now trading at $1.81, representing a 30-day decline of 63.9%. Richard's purchase history shows only 1 prior buy across all his open-market activity, making this accumulation the second documented discretionary purchase in his insider trading record. The combination of significant share count addition, sustained price deterioration, and the company's negative profitability creates a signal worth monitoring for investor patterns at this stage of the company's performance cycle.

PFO Alfieri buys 5,000 ALDX shares at $1.42; stock now $1.83, down -73.5% from 52-week high, company unprofitable.

Alfieri Michael, Principal Financial Officer, purchased 5,000 shares of Aldeyra Therapeutics at $1.42 on 2026-03-18, tripling his holdings from 2,500 to 7,500 shares. The purchase occurred in a severely depressed environment: the stock is currently priced at $1.83, down -73.5% from its 52-week high of $6.91 and down -64.5% over the trailing 30 days. The company reported a net loss of $-7,688,341.00 for its most recent fiscal year. Alfieri's prior buy at this ticker on 2025-08-13 returned -1.3% over 90 days, and his cross-ticker track record shows a 0.00% win rate over 90-day holding periods. The transaction's modest absolute value ($7,100.00) and the insider's poor prior timing history at this stock suggest this purchase does not constitute evidence of conviction-driven accumulation.

PFO Michael Alfieri buys 2,500 shares of ALDX at $5.30; first position after company losses of $-9.8M

Principal Financial Officer Michael Alfieri initiated a position of 2,500 shares at $5.30 on 2025-08-13, his first shareholding in the company. This purchase occurs while Aldeyra Therapeutics remains unprofitable with net income of $-9.8M over the most recent full fiscal year. The stock has declined 22.8% from its 52-week high of $6.98 yet has appreciated 149.5% over the past 90 days and 4.5% over 30 days, suggesting recent positive momentum despite the company's ongoing losses. As the principal financial officer, Alfieri's initial buy carries potential relevance to capital allocation decisions, though the modest position size of 2,500 shares warrants context about company magnitude and officer compensation structures.

10% owner PERCEPTIVE ADVISORS LLC sold 3.40M shares of ALDX at $1.42 on 2025-04-03, reducing stake to 5.88M shares; stock now -72.1% from 52-week high.

PERCEPTIVE ADVISORS LLC, a 10% shareholder, divested 3,400,000 shares (36.7% reduction in holdings) at $1.42 per share for $4,828,000.00. The current price of $1.95 is -72.1% from the 52-week high of $6.98, and the stock has declined 69.3% over the past 30 days and 61.8% over 90 days. Across his prior ALDX trades, the insider's timing record at this ticker has been poor: 4 of 5 prior buys resulted in negative 90-day returns, with only 1 of 5 prior buys posting a positive 90-day outcome. The company remains unprofitable with net income of $-15,112,983.00 and a market cap of $116,431,875.30. While the insider's cross-ticker track record shows strong performance (66.67% 90-day win rate, +236.3% average 90d return on 20 buys), his specific execution at ALDX has not replicated that success, and this large stake reduction occurs against significant recent price deterioration and negative fundamentals.

Director Nancy Miller-Rich purchased 922 shares in 2 transactions totaling $10,446.70; stock down 12.5% from 52-week high at $5.53

Nancy Miller-Rich, as a Director, made 2 separate purchases totaling 922 shares for $10,446.70 over a two-year span (May 2021 at $12.81 and April 2023 at $10.13), establishing an initial position from zero shares. The company is unprofitable with net income of $-16,847,572.00, and the stock currently trades at $5.53—below both transaction prices and 12.5% below its 52-week high of $6.32. The time gap between purchases (nearly two years) and the subsequent price decline to below the blended average price of $11.33 provide limited immediate signal about insider conviction at entry or near-term pricing foresight. Investors should note the unprofitable status of the underlying business alongside the modest absolute purchase volume.